Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company that specialises in the development of a new class of medications that act directly on the brain to treat hypertension and congestive heart failure, is announcing today that it has appointed Prof. Frans Leenen, a renowned cardiovascular disease specialist, to its Scientific Advisory Board.
Prof. Frans Leenen, MD, PhD, FRCPC, FAHA, is the Director of the Hypertension Clinical and Research Program at the University of Ottawa Heart Institute. He is also Professor of Medicine and Pharmacology in the Department of Medicine and the Department of Cellular and Molecular Medicine at the University of Ottawa.
He is an internationally recognised specialist in the study of the sympathetic nervous system and his research focuses on the role of brain mechanisms in hypertension and congestive heart failure and how these can be inhibited by drug therapy. He was one of the lead trial investigators for ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), the largest study ever conducted in people suffering from hypertension, with more than 42,000 volunteers participating in 600 centres throughout Canada and the United States. He has authored more than 300 scientific publications, many of which have appeared in prestigious journals.
“We urgently need to develop new classes of medicine to treat hypertension and congestive heart failure. Brain aminopeptidase A inhibitors (BAPAIs) make it possible to act directly on the brain renin-angiotensin system, which is known to play a key role in the regulation of blood pressure and cardiac function. This opens up unprecedented and promising possibilities in the fight against cardiovascular disease, which is a public health menace,” states Frans Leenen.
The Chairman and CEO of Quantum Genomics, Lionel Ségard, adds: “We are extremely honoured to welcome Prof. Frans Leenen to our scientific committee of world-renowned experts. His vast experience in cardiovascular disease, his scientific expertise in clinical research, his network and, of course, his advice will be particularly valuable for the successful development of our new class of drug candidates, especially as we are in an active phase of clinical development.”
Calendar of upcoming events
Quantum Genomics is also currently announcing its provisional timetable for the first half of 2018:
- 8 March 2018 F2IC Individual Shareholders Meeting (Bordeaux)
- 12-14 March 2018 BIO-Europe Conference in Amsterdam
- 29 March 2018(*) Publication of Financial Year 2017 Results
- 16-17 April 2018 SmallCap Event (Paris)
- 04-07 June 2018 BIO International Convention (Boston)
- 14 June 2018 (10 am) Shareholders General Meeting
- 4 October 2018(*) Publication of Results for the 1st Half of 2018
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company that specialises in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on its 20-plus years of basic and clinical research at some of the largest French laboratories (The French National Institute of Health and Medical Research (INSERM), the French National Centre for Scientific Research (CNRS), the Collège de France, and Paris-Descartes University). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of arterial hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for congestive heart failure (one in two patients diagnosed with congestive heart failure dies within five years).
Based in Paris and New York, the company is listed on the Euronext Growth exchange in Paris (FR0011648971 - ALQGC) and trades on the OTCQX market in the United States (symbol: QNNTF). Click here for more information about Quantum Genomics. Follow us on Twitter and LinkedIn.
|Lionel Ségard |
Chairman and CEO
+33 (0)1 85 34 77 70
|Marc Karako |
CFO - Investor Relations
+33 (0)1 85 34 77 70 - email@example.com
|Francis Temman |
Media Relations and Scientific Communications
+33 (0)6 50 92 21 56 - firstname.lastname@example.org
|Nathalie Boumendil |
+33 (0)6 85 82 41 95 - email@example.com
|Edison Advisors (U.S.)|
|Tirth Patel |
+1 (646) 653-7035 - firstname.lastname@example.org